Vaz F, Silva M R, Ascensao J L
Portuguese Institute of Oncology, Lisbon, Portugal.
Br J Cancer. 1995 Dec;72(6):1498-503. doi: 10.1038/bjc.1995.536.
Roquinimex (Roq) is an immunomodulator known to stimulate cellular immune responses. It is currently used for immunotherapy after bone marrow transplantation (BMT). One of the major features of this compound is an enhancement of natural killer (NK) cell activity and numbers. We studied the in vitro effect of Roq on human peripheral blood NK and adherent lymphokine-activated killer cell (ALAK) activities. In cultures supplemented with recombinant interleukin 2 (rIL-2) (1000 U ml-1) and Roq a significant increase in NK and LAK function was observed without a parallel increase in cell numbers. We also examined the generation of NK cells from human bone marrow (BM) immature progenitors, obtained by purging with 4-hydroperoxycyclophosphamide (4HC). NK cell numbers and activity were both increased when cultures with rIL-2 (10 U ml-1) were supplemented with Roq. These results confirm findings obtained in vivo and in vitro in the murine system and suggest that Roq is an active agent on these lymphoid populations. These properties and good tolerability make Roq an attractive tool for immunotherapy.
罗喹美克（Roq）是一种已知可刺激细胞免疫反应的免疫调节剂。它目前用于骨髓移植（BMT）后的免疫治疗。该化合物的主要特征之一是增强自然杀伤（NK）细胞的活性和数量。我们研究了Roq对人外周血NK和黏附性淋巴因子激活的杀伤细胞（ALAK）活性的体外作用。在补充重组白细胞介素2（rIL-2）（1000 U/ml）和Roq的培养物中，观察到NK和LAK功能显著增加，而细胞数量没有相应增加。我们还研究了用4-氢过氧环磷酰胺（4HC）清除后从人骨髓（BM）未成熟祖细胞中产生NK细胞的情况。当含有rIL-2（10 U/ml）的培养物中添加Roq时，NK细胞数量和活性均增加。这些结果证实了在小鼠系统中体内和体外获得的发现，并表明Roq对这些淋巴细胞群体是一种活性剂。这些特性和良好的耐受性使Roq成为免疫治疗的一个有吸引力的工具。
